Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

Cycle Pharmaceuticals is pleased to announce that it has signed an agreement with Baylor Genetics

December 18th, 2019|1 Comment

Health Canada has approved an updated version of the NITISINONE TABLETS’ Product Monograph

November 18th, 2019|0 Comments

Cycle Pharmaceuticals and Catalent Partner to Develop Treatments for Rare Diseases using Zydis ODT Technology

October 31st, 2019|0 Comments

NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across Australia

April 28th, 2019|0 Comments

Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in Chile

November 22nd, 2018|0 Comments

Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDA

November 19th, 2018|0 Comments

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

November 12th, 2018|0 Comments

Cycle Pharmaceuticals Receives FDA Approval for Ketorolac Tromethamine Tablets in the U.S.

August 29th, 2018|0 Comments

Aprecia Pharmaceuticals and Cycle Pharmaceuticals Partner to Develop 3D-Printed Orphan Drugs

December 12th, 2017|0 Comments

  • NITYR

Cycle Pharmaceuticals launches free trial of NITYR in the US and Partners with Cambrooke Therapeutics to Support HT-1 Patients’ dietary needs

November 10th, 2017|0 Comments

Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S.

September 19th, 2017|0 Comments

Cycle Pharmaceuticals Partners with Cardinal as the Logistic Provider for Nityr in U.S.

August 7th, 2017|0 Comments

FOLLOW US
WHY CYCLE PHARMA

We target market imbalance where we can better serve patient health needs by innovating drugs

More About Cycle